is a boutique law firm handling complex and class action litigation, including shareholder derivative litigation, securities class actions, data breach and consumer class actions.

Current Securities Class Action Cases

Federman & Sherwood regularly posts press releases about new class action securities cases, which includes the class period and deadlines for appointment of lead plaintiffs.  Please review any of the case listings  below, and if you bought a security during the class period, we invite you to return an investor certification to our office. Our link to an investor certification for any of the cases can be found below each respective press release on that company.  Once completed, please return to our office by email to or fax to (405) 239-2112. 

Current Cases

IRadimed Corporation [NASDAQ: IRMD]

Federman & Sherwood Announces the Filing of a Securities Class Action Lawsuit
Against IRadimed Corporation

Oklahoma City, OK (September 12, 2014) – On September 10, 2014, a securities class action lawsuit was filed in the United States District Court for the Southern District of Florida against IRadimed Corporation (NASDAQ: IRMD). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is July 15, 2014 through September 9, 2014. More specifically, this litigation was filed when the Company announced that it received a warning letter from the FDA requesting that the Company immediately stop all activities that misbranded or adulterated its mRidium 3860+ MRI infusion pump, mRidium 3850 MRI infusion pump, and/or the mRidium 3860 MRI infusion pump, such as the commercial distribution of the devices. This adverse news caused IRadimed's stock to fall $3.30 per share, or more than 30%, to close at $7.10 per share on September 3, 2014.

According to the lawsuit, IRadimed failed to disclose that: (a) the Company's infusion pump systems had been significantly modified, possibly affecting the safety or effectiveness of the devices; (b) as such, under applicable federal regulations the Company's products are "adulterated" and "misbranded"; (c) the Company's mRidium 3860+ infusion pump requires separate FDA clearance from the mRidium 3860 and mRidium 3850; and (d) the Company failed to disclose the material uncertainties and risks that their products were adulterated or misbranded.

Plaintiff seeks to recover damages on behalf of all IRadimed Corporation shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Monday, November 10, 2014 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

To join this class action, click here to obtain an investor certification. Once complete, please email this form to, fax to us at (405) 239-2112 or send by regular mail to Federman & Sherwood, 10205 North Pennsylvania Avenue, Oklahoma City, OK 73120, ATTN: Lynn.

Copyright © 2018 Federman & Sherwood. All Rights Reserved.